Merck KGaA Enters Partnership With China's Hengrui for Up to $1.5 Billion
By Adria Calatayud
Germany's Merck KGaA has entered into a partnership to license a cancer drug developed by China's Jiangsu Hengrui Pharmaceuticals for up to 1.4 billion euros ($1.48 billion).
Merck said Monday that the collaboration with Hengrui gives it an exclusive license outside of China to develop, manufacture and commercialize Hengrui's drug candidate HRS-1167 as well as an option to license, also outside of China, Hengrui's antibody-drug conjugate SHR-A1904. Merck also has the option to co-promote both assets in China, it said.
Hengrui will get EUR160 million upfront and will receive payments for the achievement of certain development, regulatory and commercial goals as well as tiered royalties on net sales by Merck, with total potential payments capped at EUR1.4 billion, the German life-sciences and electronics group said.
Merck said the collaboration strengthens its oncology pipeline, as HRS-1167 has shown encouraging signs of clinical activity and patient benefit in early-stage trials as a monotherapy. The drug has higher potential to combine with chemotherapy and novel agents, Merck said.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
October 30, 2023 04:44 ET (08:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy